A Phase 2 Study to Evaluate the Safety, PK, and Exploratory PD of Tildacerfont in Children With CAH

  • participants needed
  • sponsor
    Spruce Biosciences
Updated on 16 September 2023


An investigation of the safety of Tildacerfont in pediatric subjects with CAH.


This is a study to evaluate the safety of Tildacerfont in pediatric subjects with CAH. Treatment will consist of 14 days of continuous dosing followed by safety follow up.

Condition Congenital Adrenal Hyperplasia, 21-OHD
Treatment Tildacerfont
Clinical Study IdentifierNCT05128942
SponsorSpruce Biosciences
Last Modified on16 September 2023

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note